Neuropediatrics 1997; 28(1): 42-44
DOI: 10.1055/s-2007-973665
Short communications

© Hippokrates Verlag GmbH Stuttgart

Farnesylation of Batten Disease CLN3 Protein

Raju K. Pullarkat, George N. Morris
  • New York State Office of Mental Retardation and Development Disabilities, Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314-6399, USA
Further Information

Publication History

Publication Date:
13 March 2007 (online)

Abstract

The carboxyl terminal of the predicted amino acid sequence of the Batten disease CLN3 gene protein is CQLS. This motif is expected to be a site for farnesylation at the cysteine residue. In order to determine whether this is indeed farnesylated we have carried out the in-vitro prenylation of tetrapeptides CVLS, CAIL and CQLS using a farnesyl transferase preparation from bovine brain. The data shows that the CQLS is a good acceptor of a farnesyl group similar to CVLS while it is a poor acceptor of a geranylgeranyl group unlike CAIL, which is a good acceptor of a geranylgeranyl group. This suggests that the CLN3 gene product may be a farnesylated protein.

    >